Centogene_Logo.png
CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally
April 28, 2022 06:30 ET | Centogene NV
Accelerating the path from diagnosis to available treatments for rare metabolic and rare neurodegenerative diseases CENTOGENE and Takeda extend contract to continue providing access to genetic...
Centogene_Logo.png
CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development
January 20, 2022 06:30 ET | Centogene NV
CENTOGENE and Insilico Medicine will work together to identify, rank, and annotate proteins to identify novel therapeutic targets for NPC using AINPC is a rare genetic disease occurring in...
CENTOGENElogo.jpg
CENTOGENE Extends Partnership With Takeda
April 14, 2021 06:30 ET | CENTOGENE GmbH
CAMBRIDGE, Mass., ROSTOCK, Germany and BERLIN, April 14, 2021 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...
CENTOGENElogo.jpg
CENTOGENE to Report First Half 2020 Financial Results on September 23, 2020
September 16, 2020 08:30 ET | CENTOGENE GmbH
CAMBRIDGE, Mass., and ROSTOCK, Germany & BERLIN, Sept. 16, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...
CENTOGENElogo.jpg
CENTOGENE and Evotec Expand Collaboration Into Gaucher Disease
August 20, 2020 01:30 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and HAMBURG, Germany and BERLIN, Aug. 20, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that...
CENTOGENElogo.jpg
CENTOGENE and Molecular Health Announce an Exclusive Collaboration With the Aim to Transform the Development of Orphan Drugs
July 27, 2020 08:00 ET | CENTOGENE GmbH
The combination of real-life data sets in rare diseases with innovative big data/artificial intelligence/novel scientific computational knowledge will transform biomedical research, product...
CENTOGENElogo.jpg
CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares
July 09, 2020 19:19 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG) (“Centogene” or the “Company”), a commercial-stage company focused on rare diseases...
CENTOGENElogo.jpg
CENTOGENE Announces the Scientific Publication of a holistic solution in the preventive testing of COVID-19
July 09, 2020 06:30 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 09, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage diagnostics and genetic research company, today announced that...
CENTOGENElogo.jpg
CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares
July 07, 2020 18:16 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, July 07, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage company focused on rare diseases that transforms real-world...
CENTOGENElogo.jpg
CENTOGENE Announces Partnership with OESIS Network for COVID-19 PCR Testing for US School Populations
July 06, 2020 06:30 ET | CENTOGENE GmbH
CAMBRIDGE, Mass. and SANTA MONICA, Calif., July 06, 2020 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), a commercial-stage diagnostics and genetic research company, and the OESIS Network Inc, an...